Bioventus: Strategic Moves Amidst Financial Challenges Justify Hold Rating
J.P. Morgan Upgrades Bioventus(BVS.US) to Hold Rating, Raises Target Price to $13
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Analyst Ratings
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $17
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $15
J.P. Morgan Maintains Bioventus(BVS.US) With Sell Rating, Announces Target Price $12
Bioventus (BVS) Gets a Sell From J.P. Morgan
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $12
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $17
Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $17
Analysts Are Bullish on These Healthcare Stocks: Bioventus (BVS), Sight Sciences (SGHT)
Bioventus Analyst Ratings
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $12
Bioventus Analyst Ratings
Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $12
Buy Rating Affirmed: Bioventus's Strong Q2 Performance and Strategic Growth Outlook